REG - Physiomics PLC - Follow-on Contract with UK Biotech Client

PhysiomicsAnnouncement

06/08/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250806:nRSF0999Ua&default-theme=true

RNS Number : 0999U  Physiomics PLC  06 August 2025

6 August 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Physiomics Awarded Follow-on Contract with UK Biotech Client

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce the award of a second
contract by a UK-based biotech client at the forefront of AI-driven drug
development. This follows the successful completion of a previous project with
the same client, which was announced in June 2024 and fell into the Company's
Modelling and Simulation division.

Under the new contract, Physiomics will update a model previously developed
for the client, incorporating clinical data from their ongoing Phase 1 study.
The updated model will be used to support critical decisions regarding future
clinical dosing strategy. The project will leverage Physiomics' proprietary
Virtual Tumour™ platform and is expected to be completed over the next two
months. The project is valued at approximately £38,000.

Dr Peter Sargent, CEO of Physiomics, commented:

"We're delighted to be working again with this valued client and to continue
supporting the development of their oncology programme. This follow-on project
provides a strong opportunity for our Virtual Tumour platform to help guide
important clinical decisions and demonstrates the growing impact of
model-informed approaches in dose optimisation decisions."

 

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTEELFBEVLEBBB